SciSparc

SciSparc, Deere & Company, Baidu, Marathon Digital, Tesla: Why These 5 Stocks Are On Investors' Radars Today
SciSparc Signs LOI to Sell 50% Interest in Subsidiary
Sponsored
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
Sponsored
SciSparc Signs LOI to Sell 50% Interest in Subsidiary
Sponsored
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
Sponsored
SciSparc Nutraceuticals Signs Agreement With Logistics Facilities, Expected To Optimize Handling and Shipment Processes and Reduce Direct Sales Costs
Sponsored
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
Sponsored

SciSparc Recent News

SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan
Sponsored
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050. 
Sponsored
SciSparc Announces Buyback Equal To 12% Of Float
SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par value (the “Ordinary Shares”).
Sponsored
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study for Tourette Syndrome ("TS").
Sponsored
SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd.
Sponsored
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain. 
Sponsored
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
SciSparc Ltd.
Sponsored
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment
Sponsored
SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins
JV Targets Potential Drugs for Cancers and Infectious Diseases 
Sponsored
Initial Positive Results For Cocaine Addiction Treatment Announced
Photo by Annie Spratt on
Sponsored
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction
Sponsored
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
No dedicated treatment currently available for cocaine addiction
Sponsored
SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology
Sponsored
SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome
Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial In Tourette Syndrome
Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel 
Sponsored
Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
SciSparc And Clearmind Medicine Inc. Collaboration Yields Positive Results For Its Psychedelic Combination Treatment
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption
Sponsored
SciSparc Reports Developing Cannabinoids Based Acute Pain Relief Alternative To Help Counter Opioid Crisis
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA.
The Hidden Potential Of The Endocannabinoid System? SciSparc Says Its Portfolio Of Cannabinoids-Derived Drug Candidates Tap The Body's Natural System
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Originally motivated by a belief in the dangerous effects of cannabinoids, research into the endocannabinoid system has since reported a central role it plays in many processes that happen inside the human body. 
Sponsored
SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application
Image by Thom Masat on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption
Sponsored
SciSparc Files Annual Report For Year Ended December 31, 2021 And Provides Corporate Update
TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- SciSparc Ltd.
Sponsored